অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - gemcitabine hydrochloride, quantity: 227.72 mg (equivalent: gemcitabine, qty 200 mg) - injection, concentrated - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections - gemcitabine kabi is indicated for treatment of patients with locally advance or metastatic non-small cell lung cancer. gemcitabine kabi is indicated for treatment of patients with locally advance or metastatic adenocarcinoma of the pancreas. gemcitabine is also indicated for patients with 5-fu refractory pancreatic cancer. gemcitabine kabi, alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer. gemcitabine kabi, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. gemcitabine kabi, in combinatin with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum-based therapy.

কানাডা - ইংরেজি - Health Canada

biomed pharma - valacyclovir (valacyclovir hydrochloride) - tablet - 500mg - valacyclovir (valacyclovir hydrochloride) 500mg - nucleosides and nucleotides

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

trigen laboratories, inc. - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), .alpha.-tocopherol acetate, dl- (unii: wr1wpi7ew8) (.alpha.-tocopherol acetate, dl- - unii:wr1wpi7ew8), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204), biotin (unii: 6so6u10h04) (biotin - unii:6so6u10h04), iron (unii: e1uol152h7) (iron - unii:e1uol152h7), cupric sulfate (unii: lrx7aj16dt) (cupric cation - unii:8cbv67279l), docusate sodium (unii: f05q2t2ja0) - ascorbic acid 500 mg - tl-hem 150 is indicated in the treatment of most megaloblastic, macrocytic and iron-deficiency anemias, in the anemias of pregnancy, in those anemias occurring in a variety of malabsorption syndromes, and those of nutritional origin. it is a useful adjuvant in patients in whom erythropoiesis is suppressed due to severe infections, malignancies or to the toxic effects of certain chemotherapeutic agents. a deficiency of vitamin e may increase the fragility of red blood cells, with resultants enhanced hemolysis. tl-hem 150 is a hematinic preparation containing multiple ingredients essential to normal erythropoiesis, plus a stool softener to counteract the possible constipating effects of iron. vitamin c is present to aid the absorption of iron. this product is contraindicated in patients with a known hypersensitivity to any of the ingredients.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - gemcitabine hydrochloride, quantity: 1.14 g (equivalent: gemcitabine, qty 1 g) - injection, powder for - excipient ingredients: mannitol; sodium hydroxide; sodium acetate trihydrate - treatment of patients with locally advanced or metastatic non-small cell lung cancer. treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. treatment of patients with fu refractory pancreatic cancer. treatment of patients with bladder cancer, alone or in combination with cisplatin. treatment, in combination with paclitaxel, of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/ neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. treatment, in combination with carboplatin, of patients with recurrent epithelial ovarian carcinoma, who have relapsed >six months following platinum based therapy.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - filgrastim, quantity: 300 microgram - injection, solution - excipient ingredients: acetate; water for injections; polysorbate 80; sorbitol; sodium - a) to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs in doses not usually requiring bone marrow transplantation, b) for reducing the duration of neutropenia and clinical sequelae in patients undergoing induction and consolidation chemotherapy for acute myeloid leukaemia, c) for the mobilisation of autologous peripheral blood progenitor cells alone, or following myelosuppressive chemotherapy, in order to accelerate neutrophil and platelet recovery by infusion of such cells after myeloablative or myelosuppressive therapy in patients with non-myeloid malignancies, d) for the mobilisation of peripheral blood progenitor cells, in normal volunteers, for use in allogeneic peripheral blood progenitor cell transplantation, e) in patients receiving myeloablative chemotherapy, for reducing the duration of neutropenia and clinical sequelae following autologous or allogeneic bone marrow transplantation, f) for chronic administration to increase neutrophil counts and to reduce the incidence and duration of infections in patients with severe chronic neutropenia, g) in patients with hiv infection, for reversal of clinically significant neutropenia and subsequent maintenance of adequate neutrophil counts during treatment with antiviral and/or other myelosuppressive medications.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - filgrastim, quantity: 480 microgram - injection, solution - excipient ingredients: polysorbate 80; sodium; water for injections; acetate; sorbitol - a) to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs in doses not usually requiring bone marrow transplantation, b) for reducing the duration of neutropenia and clinical sequelae in patients undergoing induction and consolidation chemotherapy for acute myeloid leukaemia, c) for the mobilisation of autologous peripheral blood progenitor cells alone, or following myelosuppressive chemotherapy, in order to accelerate neutrophil and platelet recovery by infusion of such cells after myeloablative or myelosuppressive therapy in patients with non-myeloid malignancies, d) for the mobilisation of peripheral blood progenitor cells, in normal volunteers, for use in allogeneic peripheral blood progenitor cell transplantation, e) in patients receiving myeloablative chemotherapy, for reducing the duration of neutropenia and clinical sequelae following autologous or allogeneic bone marrow transplantation, f) for chronic administration to increase neutrophil counts and to reduce the incidence and duration of infections in patients with severe chronic neutropenia, g) in patients with hiv infection, for reversal of clinically significant neutropenia and subsequent maintenance of adequate neutrophil counts during treatment with antiviral and/or other myelosuppressive medications.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - filgrastim, quantity: 120 microgram - injection, solution - excipient ingredients: sorbitol; polysorbate 80; acetate; water for injections; sodium - a) to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs in doses not usually requiring bone marrow transplantation, b) for reducing the duration of neutropenia and clinical sequelae in patients undergoing induction and consolidation chemotherapy for acute myeloid leukaemia, c) for the mobilisation of autologous peripheral blood progenitor cells alone, or following myelosuppressive chemotherapy, in order to accelerate neutrophil and platelet recovery by infusion of such cells after myeloablative or myelosuppressive therapy in patients with non-myeloid malignancies, d) for the mobilisation of peripheral blood progenitor cells, in normal volunteers, for use in allogeneic peripheral blood progenitor cell transplantation, e) in patients receiving myeloablative chemotherapy, for reducing the duration of neutropenia and clinical sequelae following autologous or allogeneic bone marrow transplantation, f) for chronic administration to increase neutrophil counts and to reduce the incidence and duration of infections in patients with severe chronic neutropenia, g) in patients with hiv infection, for reversal of clinically significant neutropenia and subsequent maintenance of adequate neutrophil counts during treatment with antiviral and/or other myelosuppressive medications.

যুক্তরাজ্য - ইংরেজি - MHRA (Medicines & Healthcare Products Regulatory Agency)

numark ltd - chloramphenicol - eye drops - 5mg/1ml

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - aprepitant, quantity: 165 mg - capsule - excipient ingredients: hypromellose; poloxamer; sucrose; microcrystalline cellulose; gelatin; sodium lauryl sulfate; titanium dioxide; indigo carmine aluminium lake; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - aprepitant, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of: - highly emetogenic cancer chemotherapy. - moderately emetogenic cancer chemotherapy. aprepitant is indicated for the prevention of postoperative nausea and vomiting.

বেলজিয়াম - ইংরেজি - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

chemo iberica s.a. - hydrochlorothiazide 12,5 mg; telmisartan 40 mg - tablet - 40 mg - 12,5 mg - telmisartan 40 mg; hydrochlorothiazide 12.5 mg - telmisartan and diuretics